Ibogaine's effects typically begin within 30–60 minutes of ingestion and can last anywhere from 24 to 36 hours in total, with some residual effects persisting for days. The experience unfolds in three clinically recognized phases: an acute or "oneiric" phase, a plateau phase, and an extended afterglow period. Duration varies considerably based on dose, route of administration, individual metabolism, and whether a full flood dose or a lower sub-perceptual dose is used.

Safety Warning: Ibogaine carries serious cardiovascular risks, including QT interval prolongation and potentially fatal cardiac arrhythmias. Its long duration means medical monitoring must extend well beyond the initial hours of the experience. Cardiac screening (12-lead ECG, electrolyte panel) is considered standard protocol in clinical settings. Never attempt ibogaine administration outside of a supervised medical environment. Ibogaine is a Schedule I controlled substance in the United States, making its use, possession, and distribution federally illegal.

What Happens in the First Hour After Ingestion?

The onset phase typically begins 30 to 60 minutes after oral ingestion of a flood dose (commonly 10–25 mg/kg of ibogaine HCl or total alkaloid extract in clinical research settings). Early physical signals include nausea, ataxia (loss of coordination), and heightened sensory sensitivity. Users frequently report that sounds become unusually loud and that light feels intense. Heart rate and blood pressure changes begin during this window, which is why continuous cardiac monitoring — including telemetry — is used in research protocols such as the Stanford/VETS study published in Nature Medicine in 2024.

The onset of visual phenomena is also common within this first hour: geometric patterns, luminous tracers, and the early emergence of what researchers describe as "waking dream" or oneiric imagery. Nausea is frequent and may lead to vomiting, which some clinical guidelines account for when timing doses.

What Is the Acute "Oneiric" Phase and How Long Does It Last?

The acute phase — sometimes called the visionary or oneiric phase — generally spans hours 1 through 8 following ingestion, though it can extend to 12 hours in some individuals. This is the most intense period of the experience. Research published by Mash et al. in the Annals of the New York Academy of Sciences describes robust hallucinatory activity, introspective imagery, and emotionally significant autobiographical memory recall during this window.

Physically, the body is under considerable stress during this phase. The individual is largely immobile, often unable to walk safely due to ataxia. Eye movements (nystagmus) are common. Clinical protocols — including those used by the Global Ibogaine Therapist Alliance (GITA) — call for continuous cardiac monitoring and the presence of a trained provider throughout this entire phase, not just at peak intensity.

What Happens During the Plateau Phase (Hours 8–20)?

As the acute visionary intensity subsides, a distinct plateau phase typically sets in, lasting roughly from hours 8 through 20. The hallucinatory content diminishes, but individuals remain in an altered cognitive state characterized by heightened introspection, emotional sensitivity, and fatigue. Physical coordination begins to return gradually, though full motor stability may not be restored until the 16–24 hour mark.

Sleep is often difficult or impossible during this phase, which researchers attribute to ibogaine's known stimulant properties — it acts on serotonin transporters and sigma-2 receptors in ways that suppress REM sleep architecture. This extended wakefulness contributes significantly to post-experience fatigue. Brown and Alper's 2018 review in the American Journal of Drug and Alcohol Abuse noted that participants in observational studies consistently reported little to no sleep during the first 24 hours.

For individuals undergoing ibogaine in the context of opioid use disorder treatment, opioid withdrawal symptoms — previously acute — are frequently reported to be substantially reduced or absent by the plateau phase, an effect researchers attribute in part to ibogaine's active metabolite, noribogaine.

How Does Noribogaine Extend the Overall Duration?

Ibogaine's duration is not solely determined by the parent compound. When the liver metabolizes ibogaine, it produces noribogaine (12-hydroxyibogamine), a pharmacologically active metabolite with a significantly longer half-life. While ibogaine's plasma half-life is roughly 4–7 hours, noribogaine's half-life extends to 24–49 hours or longer depending on the individual, according to pharmacokinetic data reviewed by Ona et al. in Frontiers in Pharmacology (2020).

Noribogaine is considered responsible for much of the "afterglow" and the sustained anti-addictive effects observed in follow-up studies. It preferentially binds to kappa-opioid receptors and serotonin transporters, and its slow clearance means that the window of cardiac risk — particularly QTc prolongation — also extends well beyond the initial experience. This is why responsible clinical protocols maintain cardiac monitoring for at least 24 hours post-dosing, and some extend to 72 hours.

What Is the Afterglow Period and How Long Can It Last?

Beginning roughly 20–36 hours after ingestion, many individuals describe an afterglow period marked by emotional openness, cognitive clarity, and reduced anxiety. This phase can persist for days to weeks. In the Stanford/VETS study involving veterans with traumatic brain injury and PTSD, participants reported significant improvements in depression, anxiety, and PTSD symptom scores that persisted at the one-month follow-up, suggesting neurobiological changes that outlast the pharmacokinetic window of both ibogaine and noribogaine.

The afterglow is not a universal experience — some individuals report fatigue, emotional rawness, or difficult integration challenges during this period. Clinical guidelines recommend structured integration support beginning in this phase, including rest, nutrition, and follow-up psychological support.

Does Dose or Formulation Change the Timeline?

Yes, meaningfully. The timeline described above applies primarily to flood doses of ibogaine HCl or total alkaloid (TA) extract, typically used in addiction interruption contexts. Several dose-dependent variations are worth noting:

  • Micro or low doses (1–3 mg/kg): May produce mild mood or cognitive changes lasting 4–8 hours with minimal visionary content.
  • Mid-range doses (5–10 mg/kg): Intermediate effects, some visual phenomena, overall duration of roughly 12–18 hours.
  • Flood doses (10–25 mg/kg in research contexts): Full timeline of 24–36+ hours as described above.
  • Iboga root bark vs. ibogaine HCl: Root bark contains multiple alkaloids beyond ibogaine, and the duration and character of effects may differ. Standardizing timelines across formulations is an ongoing research challenge.

Individual factors — including CYP2D6 liver enzyme activity, body weight, overall health, and concurrent medications — can shift the timeline by several hours in either direction.

Frequently Asked Questions

Ibogaine itself is largely cleared within 24 hours, but its metabolite noribogaine can remain detectable in plasma for 24–49 hours or longer depending on individual metabolism. Some studies suggest noribogaine may persist in fatty tissue for days to weeks. Urine drug screens don't typically test for ibogaine specifically, but specialized laboratory tests can detect it.
Sleep is generally not possible during the first 24 hours due to ibogaine's stimulant properties. REM sleep suppression is well-documented in the research literature. Most individuals do not sleep until well into the plateau or early afterglow phase, often 20–30 hours after ingestion. When sleep finally comes, it is frequently described as deep and restorative.
Because noribogaine also prolongs the QTc interval, the cardiac risk window extends beyond the acute phase. Responsible clinical protocols maintain continuous cardiac monitoring for a minimum of 24 hours post-dosing, with some centers extending to 72 hours. Pre-existing QT prolongation, electrolyte imbalances, or concurrent QT-prolonging medications significantly increase risk and are contraindications in most research protocols.
No. Individual variation is significant. CYP2D6 enzyme activity — which governs how quickly ibogaine is metabolized to noribogaine — varies genetically across populations. Poor metabolizers may experience longer and more intense effects, while ultra-rapid metabolizers may clear the compound faster. Body composition, liver health, dose, and formulation all influence duration.
This is one of the most studied questions in ibogaine research. Observational studies by Brown and Alper (2018) and Novaes et al. (2022) found that opioid abstinence and reduced craving were reported by meaningful proportions of participants at 6- and 12-month follow-ups. The Stanford/VETS Nature Medicine study found improvements in PTSD and depression scores persisting at one month. However, ibogaine is not considered a permanent cure — integration support and follow-up care are emphasized in all research protocols.
Ibogaine is a Schedule I controlled substance under the U.S. Controlled Substances Act, meaning it is federally illegal to manufacture, distribute, or possess in the United States outside of an approved FDA Investigational New Drug (IND) application. It is legally available in a number of other countries, including Mexico, Canada, the Netherlands, and several others, where licensed clinics operate. Some U.S. states have begun decriminalization or legalization discussions, but no state has fully legalized it for clinical use as of 2026.
Clinical guidelines universally recommend clearing at least 3–5 days from any significant obligations following a flood dose session — not just the 24–36 hours of acute effects. The first 24 hours require complete rest and medical supervision. Days 2–3 are typically marked by fatigue and emotional processing. Days 4–7 often represent the beginning of the afterglow. Most reputable clinics build structured programming around this timeline, including pre-treatment preparation and post-treatment integration days.

Understanding the full timeline of ibogaine's effects is essential for anyone researching this compound — whether for personal decision-making, supporting a loved one, or following the science. The 24–36 hour duration, extended by noribogaine's long half-life, has direct implications for safety monitoring, logistical planning, and realistic expectations about recovery. Anyone considering ibogaine treatment is strongly encouraged to consult with a physician experienced in psychedelic medicine, review current clinical trial data at ClinicalTrials.gov, and work only within legal frameworks. The Global Ibogaine Therapist Alliance (GITA) and academic research groups publishing through peer-reviewed journals remain the most reliable sources of evolving clinical guidance.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.